Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin for Retrograde-cricopharyngeus Dysfunction
NCT06356025Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of botulinum toxin type A in Retrograde Cricopharyngeal Dysfunction (R-CPD), sponsored by AstraZeneca. Started Sep 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Retrograde Cricopharyngeal Dysfunction (R-CPD)
Beyond the preview
Go deeper on NCT06356025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06356025.